Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04606381 · ClinicalTrials.gov registry record · Phase 1
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
A Phase 1 study of Neoplasms, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 1
- Development phase
- 158
- Enrollment target
- 12
- Study locations
NCT04606381 is a Phase 1 study of Neoplasms that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 158 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (90% lower). The trial reports 12 study locations across 7 states.
The verdict
NCT04606381, a Phase 1 study of Neoplasms, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 158 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to assess the feasibility of subcutaneous (SC) administration of amivantamab based on safety and pharmacokinetics and determine a dose, dose regimen and formulation for amivantamab SC delivery.
Conditions Studied
Interventions
- DRUG Ami-LC-MD
- DRUG Ami-LC
- DRUG Ami-HC
- DRUG Ami-HC-CF
Study Locations (12)
Other
- Chungbuk National University Hospital - Cheongju-si
- Seoul National University Bundang Hospital - Seongnam-si
- Severance Hospital Yonsei University Health System - Seoul
- Samsung Medical Center - Seoul
- The Christie Nhs Foundation Trust - Manchester
- Royal Marsden Hospital - Sutton
California
- Cedars Sinai Medical Center - West Hollywood
Indiana
- Community Health Network - Indianapolis
New York
- Langone Health at NYC University, NYU School of Medicine - New York
Oregon
- Providence Portland Medical Center - Portland
Tennessee
- Sarah Cannon Research Institute - Nashville
Ontario
- University Health Network - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2020-11-10 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04606381
The ClinicalTrials.gov registry entry for NCT04606381 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (90% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 4 interventions - of which Ami-LC-MD is the first listed.
NCT04606381 reports 12 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT04606381 about?
NCT04606381 is a clinical study titled "A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies". The purpose of this study is to assess the feasibility of subcutaneous (SC) administration of amivantamab based on safety and pharmacokinetics and determine a dose, dose regimen and formulation for amivantamab SC delivery.
What is the current status of trial NCT04606381?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 158 participants. The study started on 2020-11-10. Estimated completion is 2026-12-31.
What conditions does trial NCT04606381 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT04606381?
The interventions under investigation include: Ami-LC-MD (DRUG), Ami-LC (DRUG), Ami-HC (DRUG), Ami-HC-CF (DRUG).
Who is sponsoring clinical trial NCT04606381?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04606381 being conducted?
This trial has 12 study locations across California, Indiana, New York, Oregon, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.